The effect of methylprednisolone treatment on fibrinolysis, thecoagulation system, and blood loss in cardiac surgery.

BACKGROUND/AIM The purpose of this study was to examine steroid pretreatment in order to decrease postoperative coagulopathy disorders and bleeding. MATERIALS AND METHODS In this randomized double-blinded study, the efficacy of low versus high doses of methylprednisolone on the coagulation system and postoperative bleeding was compared in patients who were undergoing cardiac surgery with cardiopulmonary bypass (CPB). The platelet response to agonists, D-dimer concentration, tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) antigens, and platelet receptors CD42b, CD62P, and CD41a were evaluated. RESULTS The platelet response to agonists was reduced. The mean concentrations of D-dimer and tPA antigen increased although PAI-1 concentration did not show any significant changes following heparin neutralization. Postoperative expression of CD42b showed no changes in comparison with preoperation values in both groups. There was a significant increase in the expression of CD62P with a methylprednisolone dose of 15 mg/kg, while there was just a slight increase with a dose of 5 mg/kg. CD41a, as a fibrinogen receptor, was increased significantly after CPB in both groups. Significant data were shown in decreasing blood loss with a high dose of methylprednisolone. CONCLUSION Methylprednisolone at a dose of 15 mg/kg reduced bleeding, probably by increasing CD62P after heparin neutralization, which can activate platelet activation in favor of better hemostasis.

[1]  N. Pathan,et al.  Steroids in cardiac surgery: right time, right dose, right patient group. , 2009, Critical care medicine.

[2]  K. Thorlund,et al.  Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. , 2008, European heart journal.

[3]  Joel D. Graham,et al.  Reducing the Effects of the Systemic Inflammatory Response to Cardiopulmonary Bypass: Can Single Dose Steroids Blunt Systemic Inflammatory Response Syndrome? , 2008, ASAIO journal.

[4]  N. Freemantle,et al.  Bleeding in cardiac surgery: the use of aprotinin does not affect survival. , 2008, The Journal of thoracic and cardiovascular surgery.

[5]  C. Eby,et al.  A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery , 2008, Transfusion.

[6]  R. McManus,et al.  Coagulopathy After Cardiac Surgery May Be Influenced by a Functional Plasminogen Activator Inhibitor Polymorphism , 2007, Anesthesia and analgesia.

[7]  S. Varghese,et al.  Platelet Functions in Cardiopulmonary Bypass Surgery. , 2005, Medical journal, Armed Forces India.

[8]  R. Whitlock,et al.  Pro: Steroids should be used for cardiopulmonary bypass. , 2005, Journal of cardiothoracic and vascular anesthesia.

[9]  K M Taylor,et al.  The systemic inflammatory response syndrome and cardiopulmonary bypass. , 2005, International journal of surgery.

[10]  A. Mahdy,et al.  Perioperative systemic haemostatic agents. , 2004, British journal of anaesthesia.

[11]  J. Copeland,et al.  The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[12]  S. Karthik,et al.  Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. , 2004, The Annals of thoracic surgery.

[13]  S. Brister,et al.  Coagulation disorders of cardiopulmonary bypass: a review , 2004, Intensive Care Medicine.

[14]  H. Shiku,et al.  Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation. , 2003, The Journal of thoracic and cardiovascular surgery.

[15]  M. Chaney.  Corticosteroids and cardiopulmonary bypass : a review of clinical investigations. , 2002, Chest.

[16]  G. Nuttall,et al.  A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery. , 2002, Anesthesia and analgesia.

[17]  O. Kemmotsu,et al.  Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery. , 2001, Thrombosis research.

[18]  S. Marasco,et al.  Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Part one: bleeding and anticoagulation issues. , 2001, Heart, lung & circulation.

[19]  P. Tassani.  Corticosteroids during operations using cardiopulmonary bypass. , 2000, Journal of clinical anesthesia.

[20]  J. Fontcuberta,et al.  Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. , 2000, Haematologica.

[21]  K M Taylor,et al.  The platelet in cardiopulmonary bypass. , 1998, The Annals of thoracic surgery.

[22]  A. Lee,et al.  Negative reexploration for cardiac postoperative bleeding: can it be therapeutic? , 1998, The Annals of thoracic surgery.

[23]  M. Ray,et al.  Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. , 1997, The Annals of thoracic surgery.

[24]  B. Spiess,et al.  Endothelial cell injury in cardiovascular surgery: the procoagulant response. , 1996, The Annals of thoracic surgery.

[25]  P. Noris,et al.  Platelet composition and function in patients undergoing cardiopulmonary bypass for heart surgery. , 1996, Haematologica.

[26]  R. P. Cochran,et al.  Individual Variations in the Fibrinolytic Response During and After Cardiopulmonary Bypass , 1995, Thrombosis and Haemostasis.

[27]  J. Loscalzo,et al.  Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. , 1995, The Annals of thoracic surgery.

[28]  B. Risberg,et al.  Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. , 1994, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[29]  B. Biagioli,et al.  Platelet function and hypothermic cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[30]  J. Mathew,et al.  Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. , 1991, Anesthesiology.

[31]  L. Harker,et al.  Bleeding complications associated with cardiopulmonary bypass. , 1990, Blood.

[32]  J. George,et al.  Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. , 1986, The Journal of clinical investigation.

[33]  A. Carpentier,et al.  Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. , 1985, The Journal of thoracic and cardiovascular surgery.